CXCR4 and breast cancer: The most frequent phenotype was (CK+/CXCR4+/JUNB+) (62.5%), as we have previously shown (90% in breast cancer and 50% in NSCLC) [30,31], and (CK+/CXCR4-/JUNB+) showed the lower percentage of positivity (18.8%) in contrast to the breast cancer [31] and NSCLC study [30], where (CK+/CXCR4+/JUNB-) was the rarest phenotype (5% and 6%, respectively).